2022-10-28 16:00Revenue and Profit Performance - Revenue for Q3 2022 was RMB 77,605 thousand, a decrease of 92.42% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2022 was a loss of RMB 486,649 thousand, a decline of 222.65% year-over-year[2] - The significant decline in revenue and profit was primarily due to a substantial decrease in demand for COVID-19 vaccines compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 was 707,395 thousand RMB, a decrease from 3,085,775 thousand RMB in the same period of 2021[17] - Net profit for the first three quarters of 2022 was -488,682 thousand RMB, compared to a net profit of 1,333,896 thousand RMB in the same period of 2021[21] - Basic and diluted earnings per share for the first three quarters of 2022 were -1.92 RMB, compared to 5.39 RMB in the same period of 2021[22] Research and Development - R&D expenses for Q3 2022 totaled RMB 229,531 thousand, an increase of 111.18% compared to the same period last year[3] - R&D expenses accounted for 295.77% of revenue in Q3 2022, an increase of 285.16 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2022 were 549,066 thousand RMB, a decrease from 655,770 thousand RMB in the same period of 2021[19] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was RMB -1,393,278 thousand, a decrease of 212.07% compared to the same period last year[3] - Cash flow from operating activities for the first three quarters of 2022 was -1,393,278 thousand RMB, compared to 1,243,273 thousand RMB in the previous year[24] - The net increase in cash and cash equivalents for Q3 2022 was -2,490,640[25] - The beginning cash and cash equivalents balance was 5,455,456[25] - The ending cash and cash equivalents balance was 2,964,816[25] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11,539,285 thousand, a decrease of 2.82% from the end of the previous year[3] - The company's cash and cash equivalents decreased to RMB 2,969,159 thousand from RMB 5,645,030 thousand, representing a decline of about 47.4%[13][15] - The total liabilities of the company as of September 30, 2022, were RMB 3,784,224 thousand, up from RMB 3,326,303 thousand, reflecting an increase of about 13.8%[16] - The company's equity attributable to shareholders decreased to RMB 7,216,494 thousand from RMB 7,995,046 thousand, a decline of approximately 9.7%[16] - The company recognized an impairment provision of RMB 526,175.9 thousand for inventory related to COVID-19 vaccines due to a significant decrease in demand compared to 2021[11] Inventory and Receivables - Inventory as of September 30, 2022, was RMB 880,460 thousand, slightly up from RMB 875,621 thousand in the previous year, indicating a marginal increase of 0.1%[13][15] - The company reported accounts receivable of RMB 312,013 thousand, which increased from RMB 157,926 thousand, showing a growth of about 97.5%[13][15] Other Financial Metrics - The weighted average return on equity was -6.53%, a decrease of 12.03 percentage points year-over-year[3] - The company reported a basic and diluted earnings per share of -RMB 1.97 for Q3 2022, a decline of 223.10% compared to the same period last year[3] - The total amount of non-recurring gains and losses for Q3 2022 was RMB 39,165 thousand[4] - Cash inflow from investment activities for the first three quarters of 2022 was 9,360,944 thousand RMB, significantly higher than 3,968,365 thousand RMB in the same period of 2021[24] - Cash outflow from investment activities for the first three quarters of 2022 was 11,284,530 thousand RMB, compared to 6,201,509 thousand RMB in the previous year[24] - Net cash flow from financing activities for the first three quarters of 2022 was 628,605 thousand RMB, down from 1,397,063 thousand RMB in the same period of 2021[24] - The company reported a tax expense of -158,171 thousand RMB for the first three quarters of 2022, compared to -43,506 thousand RMB in the previous year[19]